Novel bone-targeted Src tyrosine kinase inhibitors prevent bone loss and stimulate osteoblast activity.

被引：0
|
作者：
Boyce, B
Xing, L
Bain, S
Shen, V
Liu, C
Chen, H
Wang, Y
Shakespeare, W
Metcalf, C
Sundaramoorthi, R
Keenan, T
Bohacek, R
van Schravendijk, MR
Dalgarno, D
Iuliucci, J
Weigele, M
Sawyer, T
机构：
[1] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
[2] SkeleTech, Bothell, WA USA
[3] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2001年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S148 / S148
页数：1
相关论文
共 50 条
  • [41] Novel Selective Inhibitors Of Nuclear Export Attenuate Inflammation and Prevent Bone Mineral Density Loss In Multiple Preclinical Models Of Rheumatoid Arthritis
    Hamuza, Mwanasha
    Landesman, Yosef
    Klebanov, Boris
    Kauffman, Michael
    Shacham, Sharon
    Endres, Judith
    Fox, David A.
    McCauley, Dilara
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S732 - S732
  • [42] NVP-AAK980, a novel 6-phenylamino-2-alkylamino-purine derivative, potently inhibits the tyrosine kinase Src and bone resorption.
    Gamse, R
    Widler, L
    Missbach, M
    Buhl, T
    Kneissel, M
    Beerli, R
    Susa, M
    Green, JR
    JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 : S487 - S487
  • [43] Discovery and characterization of a novel multi-targeted tyrosine kinase inhibitor with activity against c-ret, pdgfr, c-kit and c-src
    Grand, C.
    Vankayalapati, H.
    Liu, X.
    Lamb, J.
    Sunseri, J.
    Lloyd, M.
    Bearss, D.
    EJC SUPPLEMENTS, 2006, 4 (12): : 187 - 188
  • [44] JNJ-26483327 is a novel multi-targeted tyrosine kinase inhibitor with cellular activity against EGFR, Her2, Src and VEGFR3
    Perera, T.
    Versele, M.
    Geerts, T.
    Lavrijssen, T.
    Janssens, B.
    Floren, W.
    King, P.
    Page, M.
    Freyne, E.
    Janicot, M.
    EJC SUPPLEMENTS, 2006, 4 (12): : 178 - 178
  • [45] DIRECT REGULATION OF SRC TYROSINE KINASE-ACTIVITY AND BONE-RESORPTION IN MATURE OSTEOCLASTS BY A SOLUBLE MEDIATOR PLATELET-DERIVED GROWTH-FACTOR (PDGF)
    NIEWOLNA, M
    YONEDA, T
    IZBICKA, E
    ZILBERSTEIN, A
    MUNDY, GR
    JOURNAL OF BONE AND MINERAL RESEARCH, 1993, 8 : S118 - S118
  • [46] Synthesis and activity of novel 5-substituted pyrrolo[2,3-d]pyrimidine analogues as pp60c-Src tyrosine kinase inhibitors
    Olgen, Sureyya
    Isgor, Yasemin G.
    Coban, Tulay
    ARCHIV DER PHARMAZIE, 2008, 341 (02) : 113 - 120
  • [47] Protein tyrosine kinase inhibitors block the stimulatory actions of phosphotyrosine phosphatase inhibitors to increase cell proliferation, alkaline phosphatase activity, and collagen synthesis in normal human bone cells
    Yoon, HK
    Baylink, DJ
    Lau, KH
    AMERICAN JOURNAL OF NEPHROLOGY, 2000, 20 (02) : 153 - 162
  • [48] Comparative evaluation of bone marrow cells morpho-functional activity in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors of the first and second generation
    Zhaleyko, I. O.
    Bilko, D., I
    Dyagil, I. S.
    Bilko, N. M.
    VISNYK OF DNIPROPETROVSK UNIVERSITY-BIOLOGY MEDICINE, 2014, 5 (02): : 104 - 109
  • [49] A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity
    Eda, H.
    Santo, L.
    Cirstea, D. D.
    Yee, A. J.
    Scullen, T. A.
    Nemani, N.
    Mishima, Y.
    Waterman, P. R.
    Arastu-Kapur, S.
    Evans, E.
    Singh, J.
    Kirk, C. J.
    Westlin, W. F.
    Raje, N. S.
    LEUKEMIA, 2014, 28 (09) : 1892 - 1901
  • [50] A novel Bruton’s tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity
    H Eda
    L Santo
    D D Cirstea
    A J Yee
    T A Scullen
    N Nemani
    Y Mishima
    P R Waterman
    S Arastu-Kapur
    E Evans
    J Singh
    C J Kirk
    W F Westlin
    N S Raje
    Leukemia, 2014, 28 : 1892 - 1901
12345